Donmez AD, Isik P, Cetinkaya S, Yarali N. Bone Loss in Pediatric Survivors of Acute Lymphoblastic Leukemia.
Eurasian J Med 2019;
51:38-41. [PMID:
30911254 DOI:
10.5152/eurasianjmed.2018.18196]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Accepted: 08/01/2018] [Indexed: 11/22/2022] Open
Abstract
Objective
Bone mineral density (BMD) in children may be negatively affected by acute lymphoblastic leukemia (ALL) or its treatment protocol. The aim of our study was to evaluate bone health by measuring BMD after ALL treatment.
Materials and Methods
The age, anthropometric measurements, and lumbar spine BMDs were recorded in 39 pediatric survivors of ALL, with no history of relapse, secondary malignancy, or transplantation. The lumbar spine BMD was measured by dual energy x-ray absorptiometry. The BMD risk factors, pubertal status, age at diagnosis, risk category, the time interval from the completion of the chemotherapy, and cranial radiotherapy were investigated. Serum calcium, phosphate, alkaline phosphates, magnesium, parathormone, and 25-hydroxy vitamin D levels were determined.
Results
The mean BMD value was calculated as 0.668±0.176 g/cm2. Osteopenia and osteoporosis were detected in nine patients (23.1%) and three patients (7.7%), respectively, according to previously published data of healthy age- and sex-related Turkish children's BMD values. The mean age at diagnosis of patients with ALL, having the Z-score above -1 was lower than in patients having bone defect (Z score <-1).
Conclusion
Early detection and intervention strategies to optimize bone health are essential in pediatric patients with ALL.
Collapse